The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma.

Sidsel Højklint Poulsen,Thomas Urup,Kirsten Grunnet,Ib Jarle Christensen,Vibeke Andrée Larsen,Michael Lundemann Jensen,Per Munck af Rosenschöld,Hans Skovgaard Poulsen,Ian Law

The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma.

2017

Sidsel Højklint Poulsen
Thomas Urup
Kirsten Grunnet
Ib Jarle Christensen
Vibeke Andrée Larsen
Michael Lundemann Jensen
Per Munck af Rosenschöld
Hans Skovgaard Poulsen
Ian Law

Background Glioblastoma patients show a great variability in progression free survival (PFS) and overall survival (OS). To gain additional pretherapeutic information, we explored the potential of O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET as an independent prognostic biomarker.

Keywords:

Glioblastoma
Medicine
Radiology
Pathology
Progression-free survival
Radiation therapy
Biomarker (medicine)
Positron emission tomography
Predictive value of tests
overall survival
newly diagnosed

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations